Get the Daily Brief
Latest Biotech News
GLP-1 competitive dynamics and pipeline pressure
Eli Lilly’s newest oral obesity therapy, Foundayo, is showing early sales disappointment even as the company’s injectable tirzepatide franchises continue to surge. Lilly reported $98 million in...
Novo pipeline setback and CEO response on innovation
Novo Nordisk’s CEO Maziar Mike Doustdar told investors on an earnings call that innovation is a matter of survival after a run of R&D setbacks. He pointed to “really good early signs” from...
HIV prevention revenue milestone and scrutiny of durability
Gilead reported its first-quarterly PrEP milestone, with Yeztugo exceeding $1 billion in quarterly sales for the HIV prevention franchise. In the second quarter of 2026, PrEP sales reached $1.03...
Court limits ‘duty to innovate’ claims against drugmakers
The California Supreme Court ruled in favor of Gilead, dismissing thousands of negligence claims over tenofivor-based HIV medicines and setting a precedent limiting “duty to innovate” theories....
AstraZeneca-Bristol Myers merger rumors cooled by Reuters report
A Reuters report said AstraZeneca and Bristol Myers Squibb are not having ongoing discussions about a potential merger, undercutting recent media coverage of talks. A senior source told Reuters...
Precision oncology diagnostics expand in Japan
Natera submitted its Signatera MRD test to Japan’s PMDA seeking companion diagnostic approval in muscle-invasive bladder cancer. The application is supported by data from IMvigor011, a...
China-to-US AI-discovery partnership milestone with Genentech
Recursion and Genentech announced plans to co-develop a neuroscience small-molecule discovery program after Genentech exercised a first validated target option from an AI-created validation...
M&A reshaping CNS-focused portfolios
Supernus Pharmaceuticals and Indivior agreed to merge in an all-stock transaction, combining commercial CNS portfolios and pipeline overlap across addiction, depression and Parkinson’s disease....
Regulatory pathway for gene-editing therapies highlighted by IND activity and setbacks
New FDA-ind clearance announcements and pipeline actions reflect continued momentum—and risk—around early-stage translational development. Brightpath Biotherapeutics received IND clearance for...
Biotech funding and IPO pipeline—Capital formation remains active
The biotech capital markets remained active with sizable listings and fresh financing aimed at advancing clinical programs and platform buildout. Attovia extended the sector’s IPO streak with a...
Recursion’s PI3Kα program advances into early-stage trials
Recursion Pharmaceuticals cleared an FDA IND for REC-7735, its AI-designed PI3Kα H1047R inhibitor, according to the company’s quarterly update. The IND clearance enables a phase I/II study for...
FDA moves Pluvicto earlier in prostate cancer pathway
The FDA expanded Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan) into earlier-stage metastatic hormone-sensitive prostate cancer, approving its use with androgen receptor pathway...
Curium and Lantheus agree radiopharma tie-up to form larger nuclear medicine platform
Curium has signed a definitive agreement to acquire Lantheus in a deal valued up to about $8 billion, uniting radiopharmaceutical manufacturing with Lantheus’ U.S. radiodiagnostics franchises. The...
Supernus and Indivior set merger terms for a CNS-focused company
Supernus Pharmaceuticals and Indivior have agreed to merge in an all-stock transaction that they described as a “merger of equals,” creating a new CNS-focused company. Under the terms, Indivior...
Antibody-drug conjugate licensing: Pathos AI expands cancer pipeline with Alphamab deal
Pathos AI has secured a large ADC licensing agreement with Jiangsu Alphamab Biopharmaceuticals for a TROP2/HER3 bispecific antibody-drug conjugate. The deal, described as global in scope outside...
FDA grants IND clearance for Brightpath multiple myeloma asset
Brightpath Biotherapeutics received FDA IND clearance for BP-2202, enabling the start of a first-in-human phase I trial in relapsed or refractory multiple myeloma. The company said dosing will...
DNA synthesis and AI demand lift Twist Bioscience’s results and financing
Twist Bioscience reported fiscal Q3 revenue growth and highlighted accelerating use of AI in drug discovery, then concurrently priced a $300 million public offering. The company said Q3 revenue...
Financing boost for Expedition Therapeutics COPD program reaches phase 2
Expedition Therapeutics secured a $115 million Series B financing tied to advancing its oral COPD candidate EXPD-101 through phase II. The company said the round supports clinical execution in its...
IPO and scaling push: Attovia raises on anti-itch immunology pipeline
Attovia Therapeutics extended biotech IPO momentum with a $289 million listing, bringing new capital for development of its anti-itch immunology programs. The company said the proceeds will fund...
Recoding clinical workflows: ultrasound guidance reduces neonatal feeding tube misplacement and radiation
A multicenter real-world study published in Pediatric Research reported that bedside point-of-care ultrasound (POCUS) guidance for nasojejunal tube placement in newborns reduces malposition rates...